再鼎醫藥-SB(09688.HK)任命Josh Smiley為首席運營官
格隆匯3月15日丨再鼎醫藥-SB(09688.HK)公佈，任命Josh Smiley為首席運營官。Smiley先生擁有超過26年的生物製藥行業工作經驗，包括曾在禮來公司負責財務、公司戰略、業務拓展、風險投資和全球業務服務運營。
再鼎醫藥首席執行官兼董事長杜瑩博士表示：“再鼎醫藥當前的產品管線中包含多款潛在突破性療法，公司非常高興能夠在這個激動人心的時期迎來Josh的加入。Josh此前在跨國製藥公司積累的豐富領導經驗，將助力再鼎醫藥更好地把握當下及未來的增長和拓展機遇。他將在履行公司使命的戰略規劃中發揮重要作用，幫助推動公司全球化拓展，建立多元化財務體系，以更好地履行我們將重要藥物惠及全球患者的使命。我相信，他對高道德標準和卓越運營的承諾，將助力再鼎醫藥發展成為一家領先的跨國公司的使命”。
Smiley先生將直接向杜瑩博士彙報，併成為再鼎醫藥管理委員會的主要成員。他將全面管理業務、財務和全球運營各個方面的工作。Smiley先生將在完成與當前僱主的相關休假安排後，於2022年8月1日正式就任再鼎醫藥首席運營官。
“我很高興能夠加入再鼎醫藥”。Smiley先生表示，“再鼎醫藥憑藉其在亞洲地區出色的商業化成績和全球產品開發進展，正在發展成為一家領先的全球生物技公司。再鼎醫藥的專有內部研發管線進展，及其超越原有優勢領域 — 腫瘤領域的多樣化產品管線，將為公司發展帶來巨大機遇。非常高興能在這樣一個激動人心的時期加入再鼎醫藥，幫助再鼎醫藥不斷強化現有優勢”。
Smiley先生於1995年在禮來開啟其職業生涯，在公司多個不同職能擔任領導職務，最近的職務為高級副總裁兼首席財務官。Smiley先生擁有哈佛大學歷史學學士學位。Smiley先生將移居至波士頓地區，並常駐再鼎醫藥位於馬薩諸塞州劍橋市的辦公室。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
